The P.A. Jenkins Archive: Science, Medicine, and Historical Inquiry
For more than a decade, we have maintained the P.A. Jenkins Archive as a living repository of original research, editorial synthesis, and referenced documentation spanning the frontiers of science, the practice of medicine, and the unspooling record of human inquiry. Named in honor of the late Dr. Patricia A. Jenkins—a historian of pharmacology whose work on mid‑century drug regulation reshaped how we understand the interplay between laboratory discovery and public policy—this site exists to preserve and extend that investigative tradition. Our editorial team works daily to curate materials that illuminate the evolving relationship between scientific evidence, clinical practice, and the legal frameworks that govern them.
We publish for readers who demand more than headlines: researchers, journalists, students, practicing clinicians, and engaged citizens who recognize that informed judgment requires access to the full arc of a story. Whether tracking the decades-long debates over asbestos exposure, the shifting consensus around hormone therapy, or the recent legal and scientific developments surrounding pharmaceutical safety, we aim to provide a stable, referenced foundation on which others can build their own conclusions. Each guide we produce undergoes multiple rounds of peer review by subject‑matter specialists; our timelines are built from primary sources including FDA dockets, published trial registries, and court transcripts.
Comprehensive Reference Material on Drug Safety and Regulatory History
One of our most consulted collections examines the emergence of NDMA contamination concerns and the subsequent wave of litigation that followed the recall of ranitidine products. Beginning with the early detection work by independent laboratories, we trace the sequence of epidemiological studies, the FDA’s evolving position, and the cascade of class‑action suits that now form a significant chapter in pharmaceutical risk history. Our reference materials include annotated bibliographies of the key peer‑reviewed papers, summaries of the major studies (including the Kaiser Permanente and Epi studies), and a digest of the scientific debates that have not yet reached full resolution. For those seeking a detailed chronological overview of the ranitidine litigation, our companion guide Zantac cancer lawsuit claims and scientific background provides a thorough examination of the evidence, court rulings, and ongoing research. We update that page as new pretrial rulings and scientific findings emerge, always with an eye toward the underlying science rather than the procedural maneuvers.
We do not offer legal advice, nor do we serve as a referral portal for law firms. Instead, we treat the topic as a case study in how scientific uncertainty is communicated, contested, and ultimately adjudicated. Readers who work through our material will come away with a clearer sense of what the epidemiology can and cannot say, where the regulatory record falls short, and what questions remain open for future investigation.
Timelines of Medical Science and Legal Precedent
Our timeline section—one of the most heavily used features of the archive—brings together two parallel streams: the evolution of the relevant biomedical knowledge and the series of judicial milestones that have shaped the litigation landscape. We have constructed a detailed interactive timeline for the Zantac matter that begins with the initial synthesis of ranitidine in the late 1970s, moves through the first NDMA findings in 2019, and continues through the multidistrict litigation proceedings of 2023–2026. Each entry includes hyperlinked source documents so that advanced readers can drill down into the original records. This structure allows anyone—from a statistics student learning about case‑control designs to a historian examining the role of media coverage in mass torts—to understand the sequence of events without being buried in legal jargon.
Our educational scope extends beyond any single controversy. We maintain parallel timelines for topics as diverse as the thalidomide tragedy, the development of HPV vaccines, the regulation of dietary supplements, and the history of informed consent in clinical research. Each timeline is cross‑referenced with our main reference library, creating a web of connections that reveals how patterns of evidence generation, regulatory response, and legal action recur across time and therapeutic area.
We invite you to explore the archive not as a static museum of past events but as a working collection that continues to grow. Whether you are researching a specific scientific claim, writing a paper on the sociology of pharmaceutical litigation, or simply seeking to understand the medical‑legal events that shape contemporary healthcare decisions, you will find here a curated, reliable, and independent resource—one that treats both the science and the history with the seriousness they demand.
From this context, claimants should organize records, treatment chronology, and exposure evidence before legal intake. Compliance terms: FDA; statute of limitations; class action; MDL; mass tort; plaintiff; settlement; adverse event; litigation; compensation.